Key Takeaways
- • Hexagon Bio closed a $62 million Series C financing, according to a Massinvestor report dated October 23, 2026.
- • The round was led by The Column Group, with participation from existing investors Nextech Invest, Deviation Capital, 8VC, and Canada Pension Plan Investment Board (CPP Investments).
- • Hexagon Bio is a Menlo Park, California biopharmaceutical company focused on discovering novel payload mechanisms for antibody-drug conjugates (ADCs).
Summary
Hexagon Bio, a biopharmaceutical company based in Menlo Park, California, announced the closing of a $62 million Series C financing, according to the original report published by Massinvestor on October 23, 2026. The company describes its focus as the discovery of novel payload mechanisms for antibody-drug conjugates, a class of targeted cancer therapeutics that pair an antibody with a cytotoxic payload.
The round was led by The Column Group. Existing investors Nextech Invest, Deviation Capital, 8VC, and Canada Pension Plan Investment Board (CPP Investments) also participated, indicating continued support from the company's earlier backers. The source material does not disclose the valuation, the post-money capitalization, or the specific use of proceeds, and it does not include management commentary on clinical timelines or pipeline milestones.
For institutional allocators, the participation of CPP Investments alongside venture investors such as 8VC signals that a large public pension investor is backing preclinical-stage oncology platform work in the ADC space. Further details on the company's pipeline and financing terms would be needed for a fuller assessment.
The round was led by The Column Group. Existing investors Nextech Invest, Deviation Capital, 8VC, and Canada Pension Plan Investment Board (CPP Investments) also participated, indicating continued support from the company's earlier backers. The source material does not disclose the valuation, the post-money capitalization, or the specific use of proceeds, and it does not include management commentary on clinical timelines or pipeline milestones.
For institutional allocators, the participation of CPP Investments alongside venture investors such as 8VC signals that a large public pension investor is backing preclinical-stage oncology platform work in the ADC space. Further details on the company's pipeline and financing terms would be needed for a fuller assessment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.